Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).
Gynecol Oncol
; 164(2): 437-445, 2022 02.
Article
en En
| MEDLINE
| ID: mdl-34955238
ABSTRACT
OBJECTIVES:
Knowledge on the course of symptoms patients with ovarian cancer experience is limited. We documented the prevalence and trajectories of symptoms after first-line chemotherapy using the Measure of Ovarian Symptoms and Treatment concerns (MOST).METHODS:
A total of 726 patients who received platinum-based chemotherapy for ovarian cancer were asked to complete the MOST every 3â¯months, beginning 6â¯months post-diagnosis and continuing for up to 4â¯years. We used descriptive statistics to examine temporal changes in MOST-S26 index scores for disease or treatment-related (MOST-DorT), neurotoxicity (MOST-NTx), abdominal (MOST-Abdo), and psychological (MOST-Psych) symptoms, and wellbeing (MOST-Wellbeing) and selected individual symptoms. We used group-based trajectory models to identify groups with persistently poor symptoms.RESULTS:
The median MOST-Abdo, MOST-DorT and MOST-Wellbeing score were worst at chemotherapy-end but improved and stabilised by 1, 3 and 12â¯months after treatment, respectively. The median MOST-NTx score peaked at 1â¯month after treatment before improving, while the median MOST-Psych score did not change substantially over time. Long-term moderate-to-severe fatigue (32%), trouble sleeping (31%), sore hands and feet (21%), pins and needles (20%) and anxiety (18%) were common. Trajectory models revealed groups of patients with persistent symptoms had MOST-DorT scores above 30 and MOST-NTx scores above 40 at treatment-end.CONCLUSIONS:
Although many patients report improvements in symptoms by 3â¯months after first-line chemotherapy for ovarian cancer, patients who scoreâ¯>â¯30/100 on MOST-S26-DorT orâ¯>â¯40/100 on MOST-S26-NTx at the end of chemotherapy are likely to have persistent symptoms. The MOST could triage this at-risk subset for early intervention.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Ováricas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Neoplasias Quísticas, Mucinosas y Serosas
/
Enfermedades del Sistema Nervioso Periférico
/
Fatiga
/
Carcinoma Epitelial de Ovario
/
Deterioro Cognitivo Relacionado con la Quimioterapia
/
Trastornos del Inicio y del Mantenimiento del Sueño
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Aspecto:
Patient_preference
Límite:
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Gynecol Oncol
Año:
2022
Tipo del documento:
Article